• Greater Cannabis posted a net loss of $33,376 for the quarter ended March 31, 2026, narrowing from a loss of $103,511 a year earlier.
• Operating expenses fell 23.34% to $33,376, with major costs including officers compensation of $30,000 alongside amortization, professional fees, and research and development.
• Other income and expenses was $0, versus $(59,975) a year earlier, due to a $57,920 loss on conversion of notes payable recorded in 2025.
• Revenue was unchanged at no revenue, while cash rose to $1,439 at March 31, 2026 and loans payable to related parties increased to $268,600.
• Business plan remains focused on clinical studies and commercialization of a cannabinoid-based therapeutic licensed from Shaare Zedek Scientific, with studies expected to require up to $1,000,000 and up to two years to complete.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greater Cannabis Company Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022628), on May 13, 2026, and is solely responsible for the information contained therein.